Rethinking CAP: Medicare Suspends Bidding Due To Vendor Unease
Executive Summary
Concerns expressed by potential drug distributors for the Medicare Part B competitive acquisition program (CAP) apparently triggered the Centers for Medicare & Medicaid Services' decision to place the bidding process on hold
You may also be interested in...
Part B Competitive Acquisition: CMS Bows To Pressure On ASP Exemption
Bowing to a major demand of both vendors and physicians, the Centers for Medicare & Medicaid Services will exempt Part B competitive acquisition program drug prices from average sales price calculations, at least for the first three years of the CAP
Part B Competitive Acquisition: CMS Bows To Pressure On ASP Exemption
Bowing to a major demand of both vendors and physicians, the Centers for Medicare & Medicaid Services will exempt Part B competitive acquisition program drug prices from average sales price calculations, at least for the first three years of the CAP
Medicare Part B ASP Rates Meet Physician Costs For Most Drugs, OIG Finds
Oncologists and hematologists continue to be able to purchase most drugs for use in outpatient settings at prices below the Medicare Part B reimbursement rate, even with Medicare's switch to payment at 106% of average sales price, an HHS Office of Inspector General audit found